TickerTalks
Browse all tickers →
TickerTalks›$TAK
TATAK

Takeda Pharmaceutical Company Limited

$TAK·$60B·Drug Manufacturers - Specialty & Generic·Healthcare
$18.43-2.5%YTD+20.9%1Y+29.3%
Price updated 3m ago·X counts updated 2d ago
TATAK
$TAKTakeda Pharmaceutical Company Limited
$18.43-2.51%18 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $TAK on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

18X posts · last 7 days
Sep 11Sep 27
Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-05

Takeda received FDA approval for MIMRYLO (rusfertide) in polycythemia vera, a shift in the PV treatment paradigm, and BMO raised the PTGX PT to $190 calling it validation of the peptide platform. Posters note the median 14-year survival of PV patients could give MIMRYLO an under-appreciated long duration.

Read what X is saying about $TAK

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $TAK — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

Takeda is up 21% year-to-date and 97% of its 52-week range on the FDA MIMRYLO approval and the Roche/CEO signal — the Japanese pharma major is finally re-rating.

Takeda Pharmaceutical is a $60B-cap Japanese pharma major whose late-stage oncology pipeline and PV franchise are finally being recognized by the tape.

  • Up 21% year to date and 29% over the last twelve months, at 97% of its 52-week range and 11% above the 200-day moving average.
  • Q1 (fiscal) revenue ¥1.22T grew 10% year over year at 67% gross margin and 17% operating margin, EPS ¥35.83 (local terms).
  • Q4 revenue ¥1.11T grew 6% year over year — the sequential Q1 acceleration is meaningful.
  • Trailing P/E 49 flips against the local-terms EPS run rate; free-cash-flow yield 8% is genuinely healthy.
  • Beta 0.09 — this trades on its own catalysts, not the broader tape.
  • FDA approved MIMRYLO (rusfertide) for polycythemia vera — a paradigm shift in PV treatment.
  • Roche proposed the former Takeda CEO for a board seat — a specific governance signal.
  • Highlighting late-stage oncology pipeline including Phase 3 arcotatug tavatecan (TAK-921) data at ESMO 2026.
  • Analyst-covered next-year consensus is ¥61.80 EPS on ¥4.68T revenue.

October 29 earnings will test whether the operational trajectory continues and whether guidance moves up on the MIMRYLO launch trajectory.

Agrees with X sentimentThe X sample flags the same MIMRYLO PV approval, the peptide-platform validation via the BMO PTGX target raise, and the 14-year PV survival duration angle — that lines up with the operational setup.

What to watch: October 29 print — MIMRYLO commercial launch trajectory, oncology-pipeline progress into ESMO, and any Roche-related governance or strategic development.

On the calendar: 2026-10-29 — Q2 (fiscal) earnings

adr

Read the AI verdict on $TAK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Japanese global pharma company focusing on rare disease, oncology, neuroscience, and GI drugs after the $62B Shire acquisition.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $TAK.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

What this means for $TAK

Partial — Japanese global pharma company focusing on rare disease, oncology, neuroscience, and GI drugs after the $62B Shire acquisition.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+21.4%YTD
+46.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
48.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
2.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
10.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
7.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
2.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
62.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$0.23$0.17+33.2%
Q1 2026May 13, 2026$-0.05$0.21-123.4%
Q4 2025Jan 29, 2026$0.21$0.55-61.3%
Q3 2025Oct 30, 2025$-0.02$0.44-105.7%
Next earningsThu, Oct 29·consensus EPS $0.15

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.22T+10.2%66.7%16.5%$35.83$73.8B
Q4 FY25$1.11T+5.8%48.8%4.3%$-7.92$10.1B
Q3 FY25$1.21T+6.0%54.4%16.0%$33.40$150.9B
Q2 FY25$1.11T-5.4%65.8%6.2%$-3.74$325.4B

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$4.68T$4.66T – $4.70T$61.80$15.95 – $78.748
FY28$4.75T$4.69T – $4.81T$98.94$89.36 – $104.048
FY29$4.90T$4.74T – $5.05T$121.08$116.19 – $126.144
FY30$5.13T$4.97T – $5.29T$138.22$132.63 – $144.004
FY31$5.16T$5.00T – $5.33T$161.08$154.57 – $167.823

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.97%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+5.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+10.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 3.2B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 14Duprey Lauren RusckowskiChief Transformation Officer34.5K sh$640KSellSep 2Plump Andrew StewartPresident116.2K sh$2.1MSellAug 19Plump Andrew StewartPresident19.7K sh$363KSellAug 18Greenway Nicola Deidre PetalChief Human Resources Officer13.0K sh$235KSellAug 11Shannon Elaine MaryPres., Global Supply & Quality20.4K sh$357KSellAug 10Plump Andrew StewartPresident165.4K sh$2.8MSellAug 10Farajallah Awny Samaan BotrosChief Medical Officer14.0K sh$240KSellAug 10Ibrahim Ramy Riad AhmedPresident7.3K sh$124KSellAug 10Duprey Lauren RusckowskiChief Transformation Officer47.6K sh$814KSellAug 10Pacheco Rhonda JanicePresident16.9K sh$289K
1–10 of 18
+ 20 other (13 awards · 7 returns) in window

See when $TAK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 63
AI summary

Takeda Pharmaceutical (TAK) filed a Form 3 initial statement of beneficial ownership for a newly appointed Director. The filing records the director's initial holdings in Takeda ADRs as required upon board appointment.

3New insider — initial holdingsJul 63
AI summary

Takeda Pharmaceutical (TAK) filed a second Form 3 initial statement of beneficial ownership for another newly appointed Director. Specific security amounts are in the tabular section of the form.

3New insider — initial holdingsJul 63
AI summary

Takeda Pharmaceutical (TAK) filed a third Form 3 initial statement of beneficial ownership for another newly appointed Director. Specific security amounts are in the tabular section of the form.

3New insider — initial holdingsMay 53
3New insider — initial holdingsApr 63
3New insider — initial holdingsApr 63
3New insider — initial holdingsApr 63
+ 26 other (23 6-Ks · 1 IRANNOTICE · 1 20-F · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Roche proposes former Takeda CEO for board seatreuters.com·7d agoTakeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026businesswire.com·7d agoTakeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systemsbusinesswire.com·12d agoIndia's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in Indiareuters.com·12d agoTakeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrastdefenseworld.net·14d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$EVO$TEVA$ZTS$INDV$ACB$ELAN$CRON$ETON
Voices on X · last 7 days

No standout posts about $TAK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport